Neurogene Inc.

NGNENASDAQHealthcare● Active

$28.60

+$2.11(+7.97%)

Market Cap$451934340

P/E Ratio—

52W High$37.266

52W Low$14.65

Avg Volume152K

Open$26.99

Beta2.04

Insider Trades Ownership Employees

Neurogene Inc. (NGNE) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · NGNE · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Neurogene Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

NGNE insider buying and selling by quarter

NGNE insider selling · NGNE insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

2.9M1.4M0

2023 Q4

2024 Q1

2024 Q2

2024 Q4

2025 Q1

2025 Q2

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · NGNE ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

NGNE executive sell shares · NGNE board member insider trading · NGNE insider trading SEC filing

Showing 30 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 6, 2026	Cvijic Christine Mikail President and CFO · Director	Sale	4,800	$30.07	$144K	98,440	Form 4
May 6, 2026	Cvijic Christine Mikail President and CFO · Director	Sale	4,800	$32.44	$156K	93,640	Form 4
Mar 26, 2026	Cvijic Christine Mikail President and CFO	Sale	2,558	$21.62	$55K	103,240	Form 4
Mar 26, 2026	McMinn Rachel CEO · Director	Sale	3,352	$22.07	$74K	1,344,307	Form 4
Mar 26, 2026	Jordan Julie Chief Medical Officer	Sale	828	$21.89	$18K	12,472	Form 4
Mar 13, 2026	Cobb Stuart Chief Scientific Officer	Sale	3,991	$20.41	$81K	33,303	Form 4
Mar 13, 2026	Cobb Stuart Chief Scientific Officer	Sale	2,658	$21.34	$57K	30,645	Form 4
Mar 13, 2026	Cobb Stuart Chief Scientific Officer	Sale	148	$22.08	$3K	30,497	Form 4
Mar 13, 2026	Cvijic Christine Mikail President and CFO	Sale	2,387	$20.42	$49K	107,456	Form 4
Mar 13, 2026	Cvijic Christine Mikail President and CFO	Sale	1,395	$21.25	$30K	106,061	Form 4
Mar 13, 2026	Cvijic Christine Mikail President and CFO	Sale	263	$22.02	$6K	105,798	Form 4
Feb 27, 2026	Cvijic Christine Mikail President and CFO	Sale	4,800	$25.11	$121K	109,843	Form 4
Feb 20, 2026	Cobb Stuart Chief Scientific Officer	Award	16,500	—	—	37,294	Form 4
Feb 20, 2026	Jordan Julie Chief Medical Officer	Award	4,900	—	—	13,300	Form 4
Feb 20, 2026	Cvijic Christine Mikail President and CFO	Award	22,000	—	—	114,643	Form 4
Feb 20, 2026	McMinn Rachel CEO · Director	Award	25,900	—	—	1,347,659	Form 4
May 14, 2025	Cobb Stuart Chief Scientific Officer	Sale	6,797	$15.15	$103K	20,794	Form 4
Mar 26, 2025	Cobb Stuart Chief Scientific Officer	Award	7,200	—	—	27,591	Form 4
Mar 26, 2025	Cvijic Christine Mikail President and CFO	Award	20,300	—	—	92,643	Form 4
Mar 26, 2025	Jordan Julie Chief Medical Officer	Award	8,400	—	—	8,400	Form 4
Mar 26, 2025	McMinn Rachel CEO · Director	Award	23,900	—	—	1,274,259	Form 4
Mar 13, 2025	Cvijic Christine Mikail President and CFO	Sale	4,501	$16.94	$76K	72,343	Form 4
Nov 26, 2024	Samsara BioCapital GP, LLC 10 percent owner	Purchase	2,000	$27.50	$55K	1,717,127	Form 4
Nov 26, 2024	Samsara BioCapital GP, LLC 10 percent owner	Purchase	15,219	$26.73	$407K	1,715,127	Form 4
Nov 26, 2024	Samsara BioCapital GP, LLC 10 percent owner	Purchase	10,803	$26.01	$281K	1,699,908	Form 4

Cvijic Christine Mikail

President and CFO · Director

Sale

Date

May 6

4,800

Price

$30.07

Value

$144K

View Form 4 on SEC.gov

Cvijic Christine Mikail

President and CFO · Director

Sale

Date

May 6

4,800

Price

$32.44

Value

$156K

View Form 4 on SEC.gov

Cvijic Christine Mikail

President and CFO

Sale

Date

Mar 26

2,558

Price

$21.62

Value

$55K

View Form 4 on SEC.gov

McMinn Rachel

CEO · Director

Sale

Date

Mar 26

3,352

Price

$22.07

Value

$74K

View Form 4 on SEC.gov

Jordan Julie

Chief Medical Officer

Sale

Date

Mar 26

828

Price

$21.89

Value

$18K

View Form 4 on SEC.gov

Cobb Stuart

Chief Scientific Officer

Sale

Date

Mar 13

3,991

Price

$20.41

Value

$81K

View Form 4 on SEC.gov

Cobb Stuart

Chief Scientific Officer

Sale

Date

Mar 13

2,658

Price

$21.34

Value

$57K

View Form 4 on SEC.gov

Cobb Stuart

Chief Scientific Officer

Sale

Date

Mar 13

148

Price

$22.08

Value

$3K

View Form 4 on SEC.gov

Cvijic Christine Mikail

President and CFO

Sale

Date

Mar 13

2,387

Price

$20.42

Value

$49K

View Form 4 on SEC.gov

Cvijic Christine Mikail

President and CFO

Sale

Date

Mar 13

1,395

Price

$21.25

Value

$30K

View Form 4 on SEC.gov

Cvijic Christine Mikail

President and CFO

Sale

Date

Mar 13

263

Price

$22.02

Value

$6K

View Form 4 on SEC.gov

Cvijic Christine Mikail

President and CFO

Sale

Date

Feb 27

4,800

Price

$25.11

Value

$121K

View Form 4 on SEC.gov

Cobb Stuart

Chief Scientific Officer

Award

Date

Feb 20

16,500

Price

—

Value

—

View Form 4 on SEC.gov

Jordan Julie

Chief Medical Officer

Award

Date

Feb 20

4,900

Price

—

Value

—

View Form 4 on SEC.gov

Cvijic Christine Mikail

President and CFO

Award

Date

Feb 20

22,000

Price

—

Value

—

View Form 4 on SEC.gov

McMinn Rachel

CEO · Director

Award

Date

Feb 20

25,900

Price

—

Value

—

View Form 4 on SEC.gov

Cobb Stuart

Chief Scientific Officer

Sale

Date

May 14

6,797

Price

$15.15

Value

$103K

View Form 4 on SEC.gov

Cobb Stuart

Chief Scientific Officer

Award

Date

Mar 26

7,200

Price

—

Value

—

View Form 4 on SEC.gov

Cvijic Christine Mikail

President and CFO

Award

Date

Mar 26

20,300

Price

—

Value

—

View Form 4 on SEC.gov

Jordan Julie

Chief Medical Officer

Award

Date

Mar 26

8,400

Price

—

Value

—

View Form 4 on SEC.gov

McMinn Rachel

CEO · Director

Award

Date

Mar 26

23,900

Price

—

Value

—

View Form 4 on SEC.gov

Cvijic Christine Mikail

President and CFO

Sale

Date

Mar 13

4,501

Price

$16.94

Value

$76K

View Form 4 on SEC.gov

Samsara BioCapital GP, LLC

10 percent owner

Purchase

Date

Nov 26

2,000

Price

$27.50

Value

$55K

View Form 4 on SEC.gov

Samsara BioCapital GP, LLC

10 percent owner

Purchase

Date

Nov 26

15,219

Price

$26.73

Value

$407K

View Form 4 on SEC.gov

Samsara BioCapital GP, LLC

10 percent owner

Purchase

Date

Nov 26

10,803

Price

$26.01

Value

$281K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 2

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About NGNE insider trading

NGNE insider trades

Neurogene Inc. (NGNE) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Cvijic Christine Mikail (President and CFO · Director), Cobb Stuart (Chief Scientific Officer), McMinn Rachel (CEO · Director). Over the past 12 months, 4 insiders have filed transactions with the SEC. NGNE insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Neurogene Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

NGNE insider trading · 5 questions

The insiders of Neurogene Inc. (NGNE) include executives and directors such as Cvijic Christine Mikail (President and CFO · Director), Cobb Stuart (Chief Scientific Officer), McMinn Rachel (CEO · Director), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

NGNE board member insider tradingwho are NGNE insidersNGNE insider rosterNeurogene Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026